Abstract: The present invention provides a variety of isolated peptides and peptidomimetics, which can be useful, for example, in constructing the conjugates of the invention or, where the peptide itself has biological activity, in unconjugated form as a therapeutic for treating any of a variety of cardiovascular diseases as described below. Thus, the present invention provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CRPPR (SEQ ID NO: 1) or a peptidomimetic thereof. The invention further provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CARPAR (SEQ ID NO: 5) or a peptidomimetic thereof, or amino acid sequence CPKRPR (SEQ ID NO: 6) or a peptidomimetic thereof.
Type:
Application
Filed:
March 22, 2015
Publication date:
January 28, 2016
Applicant:
SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Inventors:
Lianglin Zhang, Jason Hoffman, Erkki Ruoslahti
Abstract: According to the embodiments described herein, a SUMOylation inhibitor compound comprising a singleton scaffold is provided. In some embodiments, a method for inhibiting a SUMOylation enzyme in a cell is provided. Such a method may include administering a SUMOylation inhibitor compound to the cell. In some aspects, the SUMOylation enzyme is SUMO E1 or SUMO E2. In some aspects, the method may be used to inhibit a cancer cell in vitro (e.g., grown in culture) or in vivo (e.g., as part of a tumor in a subject). In other embodiments, a method for treating a cancer, degenerative diseases and viral infection is provided. Such a method may include administering an effective amount of a pharmaceutical composition to a subject having the cancer. The pharmaceutical composition may include a singleton SUMOylation inhibitor compound.
Type:
Grant
Filed:
May 9, 2013
Date of Patent:
January 19, 2016
Assignees:
City of Hope, Sanford-Burnham Medical Research Institute at Lake Nona
Abstract: This application relates to the modulation of host cell factors required for influenza virus replication. The application relates to compounds, including nucleic acid compounds (such as, e.g., small interfering RNAs (siRNAs)) and small molecules, that target human host cell factors involved in influenza virus replication, and the use of such compounds for modulating influenza virus replication and as antiviral agents. The application also relates to methods of treating an influenza virus infection and methods of treating or preventing a symptom or disease associated with influenza virus infection, comprising administering to a subject a composition comprising a compound, such as a nucleic acid compound (e.g., an siRNA) or small molecule, that targets a human host cell factor involved in influenza virus replication.
Type:
Grant
Filed:
December 10, 2010
Date of Patent:
January 19, 2016
Assignees:
Icahn School of Medicine at Mounta Sinai, Salk Institute for Biological Studies, Sanford-Burnham Medical Research Institute
Inventors:
Megan Shaw, Peter Palese, Adolfo Garcia-Sastre, Silke Stertz, John Young, Renate König, Sumit Chanda
Abstract: Small molecule compounds and methods for stem cell differentiation are provided herein. An example of a class of compounds that may be used to practice the methods disclosed herein is represented by enantiomerically pure isomers of compounds of Formula I: or a chirally pure stereoisomer, pharmaceutically acceptable salt, or solvate thereof, wherein R1, R2, R3, R4, R5, R5?, R6, R6?, R7, R7? are as described herein.
Type:
Grant
Filed:
March 23, 2012
Date of Patent:
January 12, 2016
Assignees:
Sanford-Burnham Medical Research Institute, Human Biomolecular Research Institute, ChemRegen, Inc.
Inventors:
Mark Mercola, John Cashman, Marion Lanier, Erik Willems, Dennis Schade
Abstract: The present invention relates to novel benzodiazepinone compounds of Formulae (I) wherein R1, R2, R4, R6, R7, R8, R9, and R10 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, methods of use of such compounds and compositions, and methods for preparing the compounds and compositions. The compounds are Group II metabotropic glutamate antagonists or allosteric modulators and are useful for the treatment of a variety of CNS disorders.
Type:
Grant
Filed:
August 29, 2012
Date of Patent:
November 24, 2015
Assignee:
SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Inventors:
John Howard Hutchinson, Leo Bleicher, Nick Cosford, Robert John Ardecky, Jiwen Zou
Abstract: Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences, such as truncated LyP-1 peptides, that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.
Type:
Application
Filed:
August 24, 2012
Publication date:
September 17, 2015
Applicant:
SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Inventors:
Erkki Ruoslahti, Tambet Teesalu, Kazuki Sugahara, Lise Roth
Abstract: Compounds of Formula (I) wherein B is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl; Y is a linker moiety selected from the group consisting of a direct bond. R, R1, R2, and R3 are each individually selected from the group consisting substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or heterocycle.
Type:
Grant
Filed:
August 27, 2012
Date of Patent:
September 1, 2015
Assignees:
Southern Research Institute, Sanford-Burnham Medical Research Institute
Inventors:
Marintha L. Heil, Nicholas D. P. Cosford, Nicholas Pagano, Peter Teriete
Abstract: Disclosed are compositions and methods useful for targeting tissue undergoing angiogenesis or to cells or tissue expressing ?v integrins. The compositions and methods are based on peptide sequences that selectively bind to and home to tissue undergoing angiogenesis or to cells or tissue expressing ?v integrins in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to tissue experiencing angiogenesis or to cells or tissue expressing ?v integrins.
Type:
Grant
Filed:
January 30, 2013
Date of Patent:
August 25, 2015
Assignee:
Sanford-Burnham Medical Research Institute
Inventors:
Erkki Ruoslahti, Kazuki Sugahara, Tambet Teesalu
Abstract: Disclosed are compositions and methods related to clot binding compounds. For example, disclosed are conjugates comprising a surface molecule and a plurality of clot binding compounds. The clot binding compounds can selectively bind to clotted plasma protein. The conjugate can, for example, cause clotting and amplify the accumulation of the conjugate in tumors. In one example, the conjugate can comprise a sufficient number and composition of clot binding compounds such that the conjugate causes clotting and amplifies the accumulation of the conjugate in tumors. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.
Type:
Grant
Filed:
December 31, 2007
Date of Patent:
August 11, 2015
Assignee:
Sanford-Burnham Medical Research Institute
Abstract: The invention provides compounds of formula I or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for inducing apoptosis or treating cancer using compounds of formula I.
Type:
Grant
Filed:
December 23, 2010
Date of Patent:
August 4, 2015
Assignees:
Wayne State University, Department of Veterans Affairs, Sanford-Burnham Medical Research Institute
Inventors:
Joseph A. Fontana, Marcia Dawson, Zebin Xia
Abstract: Methods of targeting atherosclerotic plaques using LyP-1 related peptides are provided. In some embodiments, the methods include administering a peptide comprising a LyP peptide to an animal, wherein the peptide homes to an atherosclerotic plaque, thereby targeting the atherosclerotic plaque. Also provided are methods for ameliorating a sign or symptom associated with an inflammatory condition using LyP-1 related peptides.
Type:
Grant
Filed:
June 22, 2012
Date of Patent:
June 23, 2015
Assignee:
Sanford-Burnham Medical Research Institute
Abstract: According to the embodiments described herein, a methods for inhibiting small ubiquitin-like modifier enzymes in a cell are provided. Such methods may include administering certain substituted pyrrolo[2,3-b]-quinoxalines to the cell. In some aspects, the small ubiquitin-like modifier enzyme is SUMO E1 or SUMO E2. In some aspects, the methods may be used to inhibit a cancer cell in vitro (e.g., grown in culture) or in vivo (e.g., as part of a tumor in a subject). In other embodiments, methods for treating a cancer, degenerative diseases and viral infection are provided. Such methods may include administering an effective amount of a pharmaceutical composition to a subject having cancer. The pharmaceutical composition may include a small ubiquitin-like modifier inhibitor compound. In some embodiments, the method for treating a disease may further comprise administering one or more DNA-damaging therapy in combination with administration of the pharmaceutical composition.
Type:
Grant
Filed:
May 9, 2013
Date of Patent:
June 2, 2015
Assignees:
City of Hope, Sanford-Burnham Medical Research Institute
Abstract: The present invention provides a variety of isolated peptides and peptidomimetics, which can be useful, for example, in constructing the conjugates of the invention or, where the peptide itself has biological activity, in unconjugated form as a therapeutic for treating any of a variety of cardiovascular diseases as described below. Thus, the present invention provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CRPPR (SEQ ID NO: 1) or a peptidomimetic thereof. The invention further provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CARPAR (SEQ ID NO: 5) or a peptidomimetic thereof, or amino acid sequence CPKRPR (SEQ ID NO: 6) or a peptidomimetic thereof.
Type:
Grant
Filed:
November 27, 2013
Date of Patent:
March 24, 2015
Assignee:
Sanford-Burnham Medical Research Institute
Inventors:
Lianglin Zhang, Jason A Hoffman, Erkki Ruoslahti
Abstract: Disclosed herein are Furin/PC inhibitors for inhibiting Furin and other Propprotein Convertases. Method of making the Furin/PC inhibitors, chemical and biological characterization of the Furin/PC inhibitors, and the use of the Furin/PC inhibitors to treat infectious diseases, cancers, and inflammatory/autoimmune disorders, are also disclosed.
Type:
Application
Filed:
March 14, 2013
Publication date:
February 19, 2015
Applicant:
Sanford-Burnham Medical Research Institute
Inventors:
Alex Strongin, Maurizio Pellecchia, Elisa Barile
Abstract: The present invention relates to novel benzodiazepinone compounds of Formulae (I) wherein R1, R2, R4, R6, R7, R8, R9, and R10 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, methods of use of such compounds and compositions, and methods for preparing the compounds and compositions. The compounds are Group II metabotropic glutamate antagonists or allosteric modulators and are useful for the treatment of a variety of CNS disorders.
Type:
Application
Filed:
August 29, 2012
Publication date:
January 22, 2015
Applicant:
Sanford-Burnham Medical Research Institute
Inventors:
John Howard Hutchinson, Leo Bleicher, Nick Cosford, Robert John Ardecky, Jiwen Zou
Abstract: The disclosure provides compounds and methods of using Apogossypolone derivatives for treating diseases and disorders. In particular, the disclosure provides compounds of Formula I: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and provides methods for the preparation of compounds of Formula I; and methods for treating cancer, autoimmune diseases, and inflammation by administering a compound of Formula I.
Type:
Grant
Filed:
October 7, 2010
Date of Patent:
January 20, 2015
Assignee:
Sanford-Burnham Medical Research Institute
Abstract: Disclosed are compositions and methods related to clot-binding compounds. For example, disclosed are compositions comprising a surface molecule and at least one modified clot-binding compound. The modified clot-binding compound can selectively bind to clotted plasma protein, wherein the composition causes clotting and amplifies the accumulation of the composition in tumors. The modified clot-binding compound can enhance the clotting in tumors compared to its unmodified derivative. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.
Type:
Grant
Filed:
December 20, 2010
Date of Patent:
December 16, 2014
Assignee:
Sanford-Burnham Medical Research Institute
Inventors:
Erkki Ruoslahti, Lilach Agemy, Venkata Ramana Kotamraju
Abstract: The present invention is based on the seminal discovery that several kinases play important roles in barrier pathways in somatic cell reprogramming. The present invention provides that modulating expression or activity of these kinases can significantly promote or enhance cell reprogramming efficiency. Key kinases are identified and key regulation networks involving such kinases are also identified that may be advantageously targeted to significantly increase reprogramming efficiency as well as direct differentiation of induced pluripotent stem (iPS) cells.
Type:
Application
Filed:
April 18, 2014
Publication date:
November 13, 2014
Applicant:
Sanford-Burnham Medical Research Institute